An interventional study of MRI-Guided Adaptive Radiation Therapy in Glioblastoma, sponsored by Abramson Cancer Center at Penn Medicine. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Treatment
Among 11 studies in Glioblastoma by Abramson Cancer Center at Penn Medicine — 3 open to participants now, 4 under way, none of them phase 3. Glioblastoma · Abramson Cancer Center at Penn Medicine.
Among the 11 studies in Glioblastoma by Abramson Cancer Center at Penn Medicine, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2027, is one of 4 with no phase, and was the 11th registered.
2,134 studies on the registry are indexed under Glioblastoma; 466 are open to participants now.
Browse Glioblastoma studies →3 of the 11 studies in Glioblastoma by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 22+
By country, each count listing its studies:
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 36 across 1,755 interventional studies indexed under Glioblastoma.
Median enrollment 21 across the 10 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Abramson Cancer Center at Penn Medicine is the lead sponsor of 461 studies on the registry; 88 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.
2 of the studies in Glioblastoma by Abramson Cancer Center at Penn Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05086497Abramson Cancer Center at Penn MedicineWBSI Guided Personalized Delivery of TTFields | 2027-06-30 |
| NCT06613841Abramson Cancer Center at Penn MedicineMultitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Glioblastoma by Abramson Cancer Center at Penn Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single institution single arm feasibility study of MRI-guided, personalized adaptive radiation therapy with reduced margins for patients with glioblastoma.
The goal of this study is to evaluate MRI-guided adaptive radiation therapy to personalize radiotherapy planning for patients with glioblastoma, reduce margins, minimize toxicity, and improve survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study intervention is MRI-guided adaptive radiation therapy with reduced treatment margins among patients with glioblastoma.
Radiation: MRI-Guided Adaptive Radiation Therapy
The study intervention is MRI-guided adaptive radiation therapy with reduced treatment margins among patients with glioblastoma.
Feasibility of MRI-Guided Adaptive Radiotherapy
Feasibility will be defined as the proportion of patients who complete at least 2 out of 3 planned biweekly offline MRI-guided adaptations during the 6 week course of radiation therapy without any delay in scheduled treatment delivery (or 1 of the 2 planned offline adaptation during a 3 week course). Feasibility will be considered acceptable if ≥ 70% of enrolled patients meet this criterion.
Time frame: 44 months
Patterns of Failure after Adaptive Radiation Therapy
Patterns of failure will be analyzed relative to the target volumes and dose distributions and categorized as central (in field), marginal, or out of field.
Time frame: 44 months
Overall Survival
Determine overall survival following adaptive radiation therapy and compare survival outcomes with a propensity score matched historical cohort treated with standard radiotherapy.
Time frame: 44 months
Patient-Reported Symptom Burden, Functioning, and Quality of Life
Longitudinal changes in patient reported symptoms, functional interference, neurologic function, and quality of life as assessed by validated patient reported outcome measures.
Time frame: 44 months
Rates of Clinician Reported Toxicity
Incidence and severity of treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Time frame: 44 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Sep 2030, 44 months later.
Of 131 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 44 months is below that.
Counting every sponsor, half of 149 studies reached it within 54 months; a quarter within 36 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine →